Related Articles
β‑catenin blockers enhance the effect of CDK4/6 inhibitors on stemness and proliferation suppression in endocrine‑resistant breast cancer cells
HSulf‑1 and palbociclib exert synergistic antitumor effects on RB‑positive triple‑negative breast cancer
CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review)
First clinical experience with CDK4/6 inhibitors in breast cancer therapy
Mechanisms of the CDK4/6 inhibitor palbociclib (PD 0332991) and its future application in cancer treatment (Review)